PMID- 11371225
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20210527
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 125
IP  - 6
DP  - 2001 Jun
TI  - Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu 
      status determination: application to node-negative breast cancer.
PG  - 746-50
AB  - BACKGROUND: HER-2/neu (ERBB2) gene amplification and/or overexpression is a major 
      event in human breast tumorigenesis. HER-2/neu gene alterations have been the 
      most frequently assessed prognostic factors during the last 10 years in breast 
      cancer and have recently emerged as a management decision tool and a therapeutic 
      target. There is still controversy over the best method to determine whether a 
      tumor is HER-2/neu positive. Because of the increasing demand for HER-2/neu gene 
      status determination in clinical practice, we compared HER-2/neu gene alterations 
      at the DNA level (gene amplification) and the protein level (overexpression) in a 
      panel of patients with lymph node-negative breast cancer who had received local 
      radiotherapy alone, with no adjuvant therapy. METHODS: We tested 100 excised 
      lymph node-negative breast tumors, using fluorescence in situ hybridization 
      (FISH) with a biotinylated HER-2/neu DNA probe and immunohistochemical assays 
      (IHC) with 2 different antibodies. RESULTS: The FISH frequency of HER-2/neu gene 
      amplification was 15%, and the IHC frequency of overexpression was 21%. 
      CONCLUSION: Although HER-2/neu amplification by FISH and HER-2/neu overexpression 
      by IHC correlated well in this panel of lymph node-negative breast carcinomas, 
      there were a number of discordant cases, pointing to the important need for 
      determining HER-2/neu alteration for the future management of HER-2/neu-based 
      clinical applications.
FAU - Onody, P
AU  - Onody P
AD  - E0017 INSERM/Laboratoire d'Oncogenetique, Centre Rene Huguenin, 35 rue Dailly, 
      F-92211 St Cloud, France.
FAU - Bertrand, F
AU  - Bertrand F
FAU - Muzeau, F
AU  - Muzeau F
FAU - Bieche, I
AU  - Bieche I
FAU - Lidereau, R
AU  - Lidereau R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*genetics/*metabolism/pathology
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/genetics/metabolism/pathology
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
EDAT- 2001/05/24 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/05/24 10:00
PHST- 2001/05/24 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/05/24 10:00 [entrez]
AID - 10.5858/2001-125-0746-FISHAI [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2001 Jun;125(6):746-50. doi: 10.5858/2001-125-0746-FISHAI.